Measurement of platelet aggregation, independently of patient platelet count: a flow-cytometric approach

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

DOI

  • P J Vinholt, Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark.
  • ,
  • H Frederiksen, Department of Hematology, Odense University Hospital, Odense, Denmark.
  • ,
  • A-M Hvas
  • U Sprogøe, o Department of Clinical Immunology , Odense University Hospital , Odense , Denmark.
  • ,
  • C Nielsen, o Department of Clinical Immunology , Odense University Hospital , Odense , Denmark.
Essentials •Platelet function may influence bleeding risk in thrombocytopenia, but useful tests are needed. •A flow cytometric platelet aggregation test independent of the patient platelet count was made. •Platelet aggregation was reduced in thrombocytopenic patients with hematological cancer. •High platelet aggregation ruled out bleeding tendency in thrombocytopenic patients. Summary Background Methods for testing platelet aggregation in thrombocytopenia are lacking. Objective To establish a flow-cytometric test of in vitro platelet aggregation independently of the patient's platelet count, and examine the association of aggregation with a bleeding history in thrombocytopenic patients. Patients/methods We established a flow-cytometric assay of platelet aggregation, and measured samples from healthy individuals preincubated with antiplatelet drugs, and samples from two patients with inherited platelet disorders. Then, we included 19 healthy individuals and 20 patients with platelet counts of ≤ 50 × 109 L–1, diagnosed with acute myeloid leukemia or myelodysplastic syndrome. We measured platelet aggregation and platelet activation by platelet surface expression of activated glycoprotein IIb–IIIa, P-selectin and CD63 after addition of agonists: collagen-related peptide, thrombin receptor-activating peptide (TRAP), and ADP. Results The platelet aggregation assay showed a low intraserial coefficient of variation of ≤ 3%. Similar results were obtained for platelet-rich plasma and isolated platelets at platelet counts of > 10 × 109 L–1; otherwise, platelet isolation was required. The platelet aggregation percentage decreased with increasing antiplatelet drug concentration. Platelet aggregation in patients was reduced as compared with healthy individuals: 42% (interquartile range [IQR] 27–58) versus 66% (IQR 60–67) for TRAP; 41% (IQR 25–48) versus 70% (IQR 69–72) for collagen-related peptide; and 44% (IQR 30–53) versus 65% (IQR 46–72) for ADP. Platelet activation after stimulation was reduced in patients and correlated with platelet aggregation (e.g. r = 0.78–0.81 when stimulated with collagen-related peptide). Platelet aggregation had a negative predictive value of 100% for a bleeding tendency among patients. Conclusion The established platelet aggregation assay was applicable for thrombocytopenic patients, and improved the identification of bleeding risk.
OriginalsprogEngelsk
TidsskriftJournal of Thrombosis and Haemostasis
Vol/bind15
Nummer6
Sider (fra-til)1191-1202
Antal sider12
ISSN1538-7933
DOI
StatusUdgivet - jun. 2017

Se relationer på Aarhus Universitet Citationsformater

ID: 121211442